NLRP3 and systemic-onset juvenile idiopathic arthritis: Approved for treatment of cryopyrin‐associated periodic syndromes and systemic juvenile idiopathic arthritis;Rheumatoid arthritis phase II testing terminatedAtherosclerosis phase II completed